Elevated risk for invasive meningococcal disease among persons with HIV.
Laura Miller, Lola Arakaki, Arianne Ramautar...
https://pubmed.ncbi.nlm.nih.gov/24166695/Actively Recruiting
Led by Thomas Benfield · Updated on 2021-05-06
55
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the safety and immune response of meningococcal and pneumococcal vaccines in adults living with HIV who are receiving antiretroviral treatment. This trial is a single-center, randomized controlled study designed to compare two different vaccination regimens to better understand their effects on this population. The study is investigator-initiated and focuses on long-term immunogenicity and safety outcomes. Participants are randomly assigned to receive either a two-dose regimen of Menveo a conjugate vaccine against meningococcal serogroups ACWY combined with Bexsero a vaccine against meningococcal serogroup B at day 0 and day 60, or a prime-boost regimen of Prevenar13 a 13-valent pneumococcal conjugate vaccine and Pneumovax23 a 23-valent pneumococcal polysaccharide vaccine given at day 0 and day 60. A crossover between groups occurs at day 90. All participants follow the same follow-up schedule including collection of plasma, pharyngeal swabs, and recording of any adverse events. Throughout the study, blood samples are taken at 30 days post-vaccination and yearly for five years to measure immune responses. Researchers will monitor immediate, short-term, and long-term side effects after vaccination, as well as bacterial carriage rates at baseline and day 30. The total duration of participant involvement includes the initial vaccinations, crossover, and follow-up visits to assess vaccine safety and effectiveness over time.
CONDITIONS
Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV
M
Michaela Tinggaard, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Thomas Benfield
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 60 days
Participants receive two doses of meningococcal vaccines (Menveo® and Bexsero®) and pneumococcal vaccines (Prevenar13® and Pneumovax23®) in a crossover design.
2 vaccination visits at Day 0 and Day 60
Duration - Up to 5 years
Participants are monitored for immunogenic response and adverse events up to 5 years after vaccination.
Multiple follow-up visits at Day 30, Day 90, and yearly up to 5 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Laura Miller, Lola Arakaki, Arianne Ramautar...
https://pubmed.ncbi.nlm.nih.gov/24166695/R H Pedersen, N Lohse, L Østergaard...
https://pubmed.ncbi.nlm.nih.gov/21059168/Ana Cristina C Frota, Bianca Ferreira, Lee H Harrison...
https://pubmed.ncbi.nlm.nih.gov/29100708/Jorge Lujan-Zilbermann, Meredith G Warshaw, Paige L Williams...
https://pubmed.ncbi.nlm.nih.gov/22622049/Jessica R MacNeil, Lorry G Rubin, Monica Patton...
https://pubmed.ncbi.nlm.nih.gov/27811836/Ole S Søgaard, Henrik C Schønheyder, Anne R Bukh...
https://pubmed.ncbi.nlm.nih.gov/20559037/Maria C Rodriguez-Barradas, Jose A Serpa, Iona Munjal...
https://pubmed.ncbi.nlm.nih.gov/25538270/Zitta Barrella Harboe, Mette Vang Larsen, Steen Ladelund...
https://pubmed.ncbi.nlm.nih.gov/25038114/Kuan-Yeh Lee, Mao-Song Tsai, Kuang-Che Kuo...
https://pubmed.ncbi.nlm.nih.gov/25483681/Ruth D Simmons, Peter Kirwan, Kazim Beebeejaun...
https://pubmed.ncbi.nlm.nih.gov/26654248/Thomas Benfield
Lead Sponsor